Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Jun 18  •  04:00PM ET
22.00
Dollar change
+6.00
Percentage change
37.50
%
Jun 18, 1:01 PMKardigan surges 22% on Nasdaq debut after upsized $400M IPO
Index
-
P/E
-
EPS (ttm)
-
Insider Own
-
Shs Outstand
87.67M
Perf Week
-
Market Cap
-
Forward P/E
-
EPS next Y
-
Insider Trans
-
Shs Float
-
Perf Month
-
Enterprise Value
-
PEG
-
EPS next Q
-
Inst Own
-
Perf Quarter
-
Income
-
P/S
-
EPS this Y
-
Inst Trans
-
Perf Half Y
-
Sales
-
P/B
-
EPS next Y
-
ROA
-
Perf YTD
-
Book/sh
-3.43
P/C
-
EPS next 5Y
-
ROE
-
52W High
- -
Perf Year
-
Cash/sh
-
P/FCF
-
EPS past 3/5Y
- -
ROIC
-
52W Low
- -
Perf 3Y
-
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
- -
Perf 5Y
-
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
-
Oper. Margin
-
ATR (14)
7.50
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
9.42
Sales Y/Y TTM
-
Profit Margin
-
RSI (14)
-
Recom
-
Dividend Gr. 3/5Y
- -
Current Ratio
9.42
EPS Q/Q
-
SMA20
0.00%
Beta
-
Target Price
-
Payout
-
Debt/Eq
0.05
Sales Q/Q
-
SMA50
0.00%
Rel Volume
-
Prev Close
16.00
Employees
210
LT Debt/Eq
0.03
Earnings
-
SMA200
0.00%
Avg Volume
-
Price
22.00
IPO
Jun 18, 2026
Option/Short
No / No
EPS/Sales Surpr.
- -
Trades
Volume
5,828,662
Change
37.50%
Jun-18-26 02:03PM
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its "Cardiac Intelligence" platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.